Zika Virus Vaccines

Zika Virus Vaccines Market Outlook

The global Zika virus vaccines market is projected to reach a value of approximately USD 1.5 billion by 2035, with a compound annual growth rate (CAGR) of around 5.3% during the forecast period from 2025 to 2035. The growth of this market is primarily driven by increasing government initiatives and funding to develop Zika vaccines due to the rising prevalence of Zika virus infections in various regions, particularly in Latin America and Southeast Asia. The global health community is putting significant resources into research and development (R&D) efforts to combat the virus, especially in light of its potential to cause congenital disabilities and other severe health issues. Additionally, the increasing awareness among the public and healthcare professionals about the Zika virus and its consequences is further propelling the demand for effective vaccination solutions. Moreover, advancements in vaccine technologies, including mRNA and DNA vaccines, are also playing a pivotal role in the market's growth.

Growth Factor of the Market

Several factors contribute to the growth of the Zika virus vaccines market. First and foremost, the heightened incidence of Zika virus cases in various parts of the world, especially during outbreaks, has compelled health authorities to prioritize vaccine development as a preventive measure. Furthermore, the ongoing research and trials for innovative vaccine types, such as DNA and mRNA vaccines, are promising and garnering substantial investment and interest from pharmaceutical companies and research institutions. The increasing collaboration between governments, public health organizations, and the private sector is resulting in accelerated vaccine development timelines. Additionally, the rising awareness amongst pregnant women regarding the risks posed by the Zika virus and its potential to cause microcephaly in newborns has escalated the demand for vaccination. Lastly, regulatory support and expedited approval pathways for Zika vaccines are propelling the market's expansion, allowing for quicker access to the vaccines for affected populations.

Key Highlights of the Market

• The worldwide Zika virus vaccines market is expected to exceed USD 1.5 billion by 2035.
• The CAGR for the market is anticipated to be around 5.3% from 2025 to 2035.
• Increased investment in vaccine R&D has led to diverse vaccine types under development.
• Heightened awareness and educational campaigns regarding Zika virus risks are enhancing vaccine uptake.
• Collaborative efforts between governments and private companies are accelerating the pace of vaccine development.

By Vaccine Type

Inactivated Virus Vaccine:

The inactivated virus vaccine is a traditional method of vaccine development, involving the use of killed Zika virus particles to stimulate an immune response without causing disease. This vaccine type has been under significant research as it mimics the natural infection closely, which helps in generating a robust immune response. The inactivated virus vaccine is advantageous as it often has a well-established safety record and does not have the risk of reverting to a pathogenic form, making it a preferred choice for vulnerable populations, particularly pregnant women. However, the development process can be lengthy and resource-intensive, which may delay its availability compared to newer vaccine technologies.

DNA Vaccine:

DNA vaccines represent a novel approach in combating viral infections, including Zika. By using engineered plasmid DNA to induce an immune response, this type of vaccine has shown promise in preclinical studies. The primary advantage of DNA vaccines is their ability to elicit both humoral and cellular immune responses, potentially leading to long-lasting immunity. Moreover, the rapid design and production capabilities of DNA vaccines make them appealing, especially when facing emerging infectious diseases like Zika. Challenges remain, including ensuring optimal delivery methods and overcoming regulatory hurdles, but the potential benefits position DNA vaccines as a strong contender in the Zika vaccine landscape.

Live Attenuated Vaccine:

Live attenuated vaccines involve the use of a weakened form of the virus to stimulate an immune response without causing disease. This type of vaccine is known for its ability to induce strong and long-lasting immunity, often requiring fewer doses than other vaccine types. The potential for enhanced effectiveness in eliciting a broad immune response is a significant advantage of live attenuated vaccines. However, safety concerns arise, especially regarding the risk of the attenuated virus reverting to a virulent form or causing disease in immunocompromised individuals. Despite these challenges, research continues to evaluate live attenuated Zika vaccines for their efficacy and safety profiles in various populations.

Subunit Vaccine:

Subunit vaccines consist of purified components of the Zika virus, such as proteins, which can provoke an immune response without introducing live virus. This safety profile makes subunit vaccines particularly attractive for populations at high risk, including pregnant women. The development of subunit vaccines has gained traction due to advancements in recombinant DNA technology, allowing for efficient production and scaling. Although they may require adjuvants to enhance the immune response, subunit vaccines have the potential to be safer and more stable compared to whole virus vaccines. Ongoing trials are assessing the effectiveness of subunit Zika vaccines in various demographic groups.

mRNA Vaccine:

mRNA vaccines have emerged as a groundbreaking technology in the vaccine landscape, especially highlighted during the COVID-19 pandemic. This type of vaccine utilizes synthetic messenger RNA to instruct cells to produce Zika virus proteins, thereby stimulating an immune response. The advantages of mRNA vaccines include rapid development, high efficacy, and the ability to produce large quantities in a short time. Furthermore, mRNA vaccines do not integrate into the host genome, posing no risk of altering DNA. As research progresses, mRNA Zika vaccines are being evaluated for their potential to provide a robust and long-lasting immune response, making them an exciting frontier in Zika virus vaccination strategies.

By End User

Hospitals:

Hospitals play a pivotal role in the administration of Zika virus vaccines, particularly in regions experiencing outbreaks. They are equipped with the necessary infrastructure and medical personnel to handle vaccination campaigns effectively. Hospitals often collaborate with public health authorities to ensure that vaccinations are distributed to those most at risk, including pregnant women and travelers to endemic regions. The presence of specialized clinics within hospitals allows for targeted education and counseling regarding the Zika virus and vaccination. Furthermore, hospitals are integral in monitoring vaccine efficacy and safety, ensuring that any adverse effects are reported and addressed promptly.

Clinics:

Clinics serve as essential healthcare facilities where individuals can receive Zika virus vaccinations conveniently. They often cater to specific populations, including travelers, and provide tailored healthcare services related to infectious diseases. Clinics enable more accessible vaccination for communities, particularly in remote or underserved areas. The ability to integrate Zika vaccination into routine healthcare services enhances public health efforts and vaccination rates. Additionally, clinics often serve as educational hubs, equipping patients with vital information about the Zika virus and its implications on health, especially for expectant mothers.

Research Institutes:

Research institutes are crucial players in the Zika virus vaccines market as they spearhead innovations and advancements in vaccine technologies. These institutions conduct pivotal clinical trials, assess vaccine safety and effectiveness, and explore novel approaches to immunization. Collaborations between pharmaceutical companies and research institutes enhance the speed of vaccine development and ensure that vaccines meet regulatory standards. Research institutes also contribute to the global knowledge base by publishing findings and sharing data related to the epidemiology of the Zika virus and its vaccine candidates. The continuous research efforts foster a better understanding of the virus and pave the way for future advancements in vaccination strategies.

Others:

This category encompasses various entities involved in the Zika virus vaccination process, including non-profit organizations, governmental health agencies, and educational institutions. Non-profit organizations often participate in advocacy, awareness campaigns, and funding initiatives to support vaccine development and distribution. Governmental health agencies play a crucial role in formulating policies and guidelines for vaccination programs. Educational institutions contribute by providing training for healthcare professionals on Zika virus management and vaccination protocols. Together, these organizations enhance the overall framework for addressing Zika virus outbreaks and ensuring the successful rollout of vaccines to affected populations.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies are critical distribution channels for Zika virus vaccines, ensuring that vaccines are readily available within healthcare settings where they are most needed. These pharmacies typically manage vaccine inventories, maintain cold chain storage, and facilitate the administration of vaccines to patients. The integrated approach of hospital pharmacies allows healthcare providers to monitor patients effectively, ensuring timely follow-up and booster doses as required. Moreover, the presence of trained pharmacists in hospitals can enhance patient education regarding the Zika virus and the importance of vaccination, improving overall public health outcomes.

Retail Pharmacies:

Retail pharmacies serve as vital access points for the public to obtain Zika virus vaccines, particularly for individuals who may face barriers to visiting hospitals or clinics. With an increasing number of people seeking vaccinations outside traditional healthcare settings, retail pharmacies can provide convenient services and extended hours. Additionally, retail pharmacists are often well-positioned to offer advice and information on Zika virus prevention and vaccination. Collaborations between retail pharmacies and public health organizations can further enhance vaccination outreach, especially in communities with limited access to healthcare services.

Online Pharmacies:

Online pharmacies represent a growing distribution channel for Zika virus vaccines, particularly as digital healthcare solutions become more mainstream. The convenience of ordering vaccines online can serve to increase vaccination rates, especially among individuals hesitant to visit physical pharmacies or clinics. However, the distribution of vaccines through online channels necessitates rigorous regulatory oversight to ensure safety, efficacy, and proper handling during shipping. Online pharmacies can also provide educational resources and facilitate telehealth consultations, allowing individuals to receive personalized advice and guidance regarding Zika vaccination.

Others:

The "Others" category encompasses various alternative distribution channels that may include community health organizations, mobile vaccination units, and governmental health initiatives. Community health organizations often engage directly with populations at risk, conducting outreach programs to educate and vaccinate individuals in need. Mobile vaccination units enable healthcare providers to reach remote or underserved areas, ensuring that vaccinations are accessible to those who may face geographic barriers. Governmental health initiatives often collaborate with local entities to develop and implement vaccination campaigns, thereby enhancing public health efforts in combating Zika virus outbreaks.

By Geography

North America:

North America holds a prominent position in the Zika virus vaccines market, primarily driven by the United States and Canada. The region has witnessed increased governmental support for vaccine research and development, especially in response to previous Zika virus outbreaks. The establishment of collaborations between research institutions and pharmaceutical companies has accelerated the development and clinical testing of promising vaccine candidates. Moreover, public health campaigns aimed at raising awareness about the Zika virus and its implications have further propelled vaccine uptake. The North American market is projected to grow at a CAGR of approximately 4.8% during the forecast period, with anticipated investments in vaccine distribution infrastructure.

Europe:

Europe presents a significant opportunity for the Zika virus vaccines market, particularly among European Union member states where public health initiatives are prioritized. The European region has experienced a growing emphasis on infectious disease prevention, leading to increased funding for vaccine research and development. The presence of established pharmaceutical companies in Europe enhances the potential for advanced vaccine technologies, including mRNA and DNA vaccines. Additionally, ongoing collaborations between public health authorities and the research community are critical for effective vaccine rollout strategies. The European Zika virus vaccines market is expected to register a CAGR of around 5% during the forecast period.

Asia Pacific:

The Asia Pacific region is witnessing a notable rise in Zika virus cases, making it an essential market for vaccine development and distribution. Countries such as Brazil and Mexico have been significantly impacted by Zika outbreaks, prompting heightened focus on vaccine research and public health measures. The presence of numerous biotech companies and research institutions in countries like India and Australia fosters innovation in vaccine technologies. Furthermore, increasing public health awareness and education regarding Zika transmission and prevention are likely to enhance vaccination efforts in the region. The Asia Pacific Zika virus vaccines market is projected to grow at a CAGR of approximately 6.2% from 2025 to 2035.

Latin America:

Latin America is the epicenter of Zika virus outbreaks, making it a critical region for vaccine development and distribution. Countries like Brazil and Colombia have experienced significant Zika virus cases, leading to heightened governmental and international efforts to develop effective vaccines. The collaboration between national health authorities and global health organizations facilitates robust vaccination campaigns, ensuring that at-risk populations receive timely immunization. Furthermore, increasing investment in healthcare infrastructure enhances the capacity for vaccine distribution in rural and underserved areas. The Latin America Zika virus vaccines market is expected to experience a CAGR of approximately 6.5% during the forecast period.

Middle East:

The Middle East presents a relatively emerging market for Zika virus vaccines, with ongoing efforts to assess and address public health challenges related to emerging infectious diseases. The region has not faced significant Zika outbreaks to date, but the potential for future cases remains a concern for health authorities. Increased awareness and readiness from governmental health agencies are essential for preparing the healthcare infrastructure for potential Zika outbreaks. Growing collaborations with international health organizations contribute to vaccine research initiatives aimed at preventing the introduction and spread of the Zika virus. The Middle East market is projected to grow at a slower CAGR of approximately 3.3% during the forecast period.

Africa:

Africa is exploring the impacts of Zika virus outbreaks, particularly in regions with favorable mosquito breeding conditions. The continent is experiencing growing awareness about the Zika virus, prompting public health authorities to prioritize vaccine development and research. Collaborative efforts between governments, local health organizations, and international health bodies are facilitating vaccination campaigns targeting at-risk populations. The potential for Zika virus transmission during local outbreaks necessitates readiness and a strategic approach to vaccination. The Africa Zika virus vaccines market is expected to grow at a CAGR of approximately 5.6% during the forecast period, driven by increasing investments in healthcare and vaccine distribution.

Opportunities

The Zika virus vaccines market is poised for significant growth due to multiple emerging opportunities. One of the most prominent opportunities lies in technological advancements in vaccine development. With the success of novel vaccine platforms, such as mRNA and DNA vaccines, there is potential for faster vaccine production and more effective immune responses. As researchers continue to innovate, the Zika virus vaccines can benefit from the lessons learned during the COVID-19 vaccine development, improving not only efficacy but also public acceptance of new vaccine technologies. Additionally, the increasing public and governmental commitment to combatting infectious diseases enhances funding opportunities for research and development of Zika vaccines, which can help expedite the timeline for bringing these vaccines to market.

Moreover, as awareness surrounding the Zika virus continues to grow globally, there is an opportunity to engage in educational initiatives that promote vaccination. Targeted campaigns aimed at pregnant women and travelers to endemic regions can significantly increase vaccine uptake. Collaborations between public health organizations and community-based entities can further enhance outreach efforts, ensuring that vulnerable populations receive timely access to vaccinations. Furthermore, the expansion of healthcare infrastructures in developing countries presents opportunities for vaccine distribution and education, fostering a comprehensive approach to Zika virus prevention and control. The combination of advancing technologies, increasing awareness, and enhanced distribution channels positions the Zika virus vaccines market for promising growth in the coming years.

Threats

Despite the promising outlook for the Zika virus vaccines market, several threats could hinder its growth trajectory. One of the most significant threats is the potential for vaccine hesitancy among the public, particularly in light of misinformation and mistrust regarding vaccination. The spread of false narratives surrounding vaccine safety and efficacy may deter individuals from seeking vaccinations, undermining public health efforts. Additionally, geopolitical factors, such as armed conflicts and political instability in endemic regions, can disrupt vaccine distribution and access, leading to challenges in reaching at-risk populations. Furthermore, the emergence of new variants of the Zika virus or other vector-borne diseases could complicate vaccine development and public health strategies, requiring ongoing vigilance and adaptability in vaccination protocols.

Another pressing concern is the regulatory landscape surrounding vaccine approvals. While there is increasing collaboration among governments and health organizations, navigating the complex regulatory environment can be challenging and time-consuming. Delays in approvals or modifications to regulatory frameworks may impede the timely availability of vaccines in critical regions. Lastly, funding limitations for research and development are a potential restrainer, particularly in low-resource settings. Proposals for innovative vaccines may struggle to secure financing, ultimately impacting the progression of vaccine candidates through the development pipeline.

Competitor Outlook

• Sanofi
• GlaxoSmithKline (GSK)
• Inovio Pharmaceuticals
• Moderna, Inc.
• Takeda Pharmaceutical Company
• Emergent BioSolutions
• Valneva SE
• BioNTech SE
• Novavax, Inc.
• Institut Pasteur
• Vaxart, Inc.
• ISU Abxis
• ReiThera S.r.l.
• CureVac AG
• Hawai‘i Biotech, Inc.

The competitive landscape of the Zika virus vaccines market is characterized by the presence of several key players actively engaged in research, development, and commercialization of vaccines targeting the Zika virus. Major pharmaceutical companies, such as Sanofi and GlaxoSmithKline, have established themselves as frontrunners in the vaccine development arena, leveraging their extensive research capabilities and resources to create effective Zika vaccines. These companies are not only investing in traditional vaccine platforms but also exploring innovative approaches, including mRNA and DNA technologies, to enhance the immune response and expedite vaccine availability. The competition among these companies is expected to intensify as they seek to capture market share and respond to the urgent need for effective vaccination against Zika virus outbreaks.

Inovio Pharmaceuticals is one of the noteworthy players focusing on DNA vaccine technology, with promising candidates undergoing clinical trials. Their approach emphasizes speed and safety, which aligns with the increasing need for accessible vaccines in endemic regions. Similarly, Moderna has gained attention for its mRNA vaccine platform, leveraging its success during the COVID-19 pandemic to expedite efforts in Zika vaccine development. The innovative nature of these companies positions them well in the competitive landscape, as they seek to translate technological advancements into effective vaccines against the Zika virus.

Takeda Pharmaceutical Company and Emergent BioSolutions are also key competitors, actively pursuing partnerships and collaborations to advance their Zika vaccine candidates. Both companies aim to address public health concerns by integrating comprehensive research strategies and leveraging their global networks to ensure timely vaccine distribution. Additionally, smaller biotech companies such as Valneva SE and CureVac AG are making significant strides in Zika vaccine development, illustrating the dynamic and competitive nature of the market. The collaboration between larger pharmaceutical firms and smaller biotech entities is fostering a collaborative ecosystem that accelerates innovation and enhances overall vaccine development efforts.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Sanofi
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 ISU Abxis
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 CureVac AG
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Valneva SE
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 BioNTech SE
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Vaxart, Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Moderna, Inc.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Novavax, Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 ReiThera S.r.l.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Institut Pasteur
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Emergent BioSolutions
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 GlaxoSmithKline (GSK)
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Inovio Pharmaceuticals
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Takeda Pharmaceutical Company
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Hawai‘i Biotech, Inc.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Zika Virus Vaccines Market, By End User
    • 6.1.1 Hospitals
    • 6.1.2 Clinics
    • 6.1.3 Research Institutes
    • 6.1.4 Others
  • 6.2 Zika Virus Vaccines Market, By Geography
    • 6.2.1 North America
    • 6.2.2 Europe
    • 6.2.3 Asia Pacific
    • 6.2.4 Latin America
    • 6.2.5 Middle East
    • 6.2.6 Africa
  • 6.3 Zika Virus Vaccines Market, By Vaccine Type
    • 6.3.1 Inactivated Virus Vaccine
    • 6.3.2 DNA Vaccine
    • 6.3.3 Live Attenuated Vaccine
    • 6.3.4 Subunit Vaccine
    • 6.3.5 mRNA Vaccine
  • 6.4 Zika Virus Vaccines Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies
    • 6.4.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Zika Virus Vaccines Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Zika Virus Vaccines market is categorized based on

By Vaccine Type

• Inactivated Virus Vaccine
• DNA Vaccine
• Live Attenuated Vaccine
• Subunit Vaccine
• mRNA Vaccine

By End User

• Hospitals
• Clinics
• Research Institutes
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

By Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa

Key Players

• Sanofi
• GlaxoSmithKline (GSK)
• Inovio Pharmaceuticals
• Moderna, Inc.
• Takeda Pharmaceutical Company
• Emergent BioSolutions
• Valneva SE
• BioNTech SE
• Novavax, Inc.
• Institut Pasteur
• Vaxart, Inc.
• ISU Abxis
• ReiThera S.r.l.
• CureVac AG
• Hawai‘i Biotech, Inc.